Biosimilars | Market Events and Forecast | Oncology | 2024
In 2022, sales of branded MAb biologics in oncology exceeded $43 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled approximately $5.5 billion. Throughout the 2022-2032 forecast period, increasing numbers of branded biologics will lose patent protection, and biosimilars will enter the market and erode both patient share and drug prices. We present our forecasts for key reference brands and their biosimilars by molecule and country / region.
Related Market Assessment Reports
Report
Chimeric Antigen Receptor (CAR) T-Cell Therapy – Access & Reimbursement – Access & Reimbursement – Chimeric Antigen Receptor (CAR) T-Cell Therapy (US)
Ever since Novartis’s Kymriah became the first chimeric antigen receptor (CAR) T-cell therapy approved by the FDA for a cancer indication (acute lymphoblastic leukemia) in 2017, this class of…
